a public good project by the
Synthesis
Company
of California

© 2026

M. Spencer | doi.page

0 works0 citations0 h-index

M. Spencer

Johnson & Johnson (United States)(US)Caris Life Sciences (United States)(US)Janssen (United States)(US)

Publications by Year

Research Areas

Multiple Myeloma Research and Treatments, Prostate Cancer Treatment and Research, Economic and Financial Impacts of Cancer, Inflammatory Bowel Disease, Acute Ischemic Stroke Management

Most-Cited Works

→ Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practice(2018)16 cited
→ Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma(2025)8 cited
→ A systematic review of noninferiority margins in oncology clinical trials(2021)7 cited
→ PCN116 Mapping FACT-P to EQ-5D in a Large Cross-Sectional Study of Metastatic Castrate-Resistant Prostate Cancer Patients(2012)3 cited
→ 1039 Natalizumab Reduces the Hospitalization Rate in Moderate to Severe Crohn's Disease Patients: A Pooled Analysis of the ENACT-1 and ENCORE Studies(2008)3 cited
→ Effects of Intensive Blood Pressure Lowering on Brain Swelling in Thrombolyzed Acute Ischemic Stroke: The ENCHANTED Results(2025)3 cited

→ MA2 Mapping Fact-P to Country Specific Patient Health Status Measured by EQ-5D in Metastatic Castrate Resistant Prostate Cancer Patients(2011)

2 cited

→ PND10 Faster Cognitive Decline is Associated With Decreasing Survival in Patients With Alzheimer'S Disease(2012)2 cited

→ PCN101 A Cost-Effectiveness Analysis for Second-Line Treatment of Relapsed/Refractory (RR) Multiple Myeloma (MM) in the United Kingdom(2011)2 cited

→ PCN121 Decitabine Reduces Transfusion Dependence in Older Patients With Acute Myeloid Leukaemia: Results From a Post-Hoc Analysis of a Randomised Phase III Trial(2012)2 cited